Multiple analogues or mimetics of FGF21 have been developed to solve this problem, some of which have completed phase I clinical trials with a noticeable improvement in obesity and T2D‐related symptoms in patients.51, 52. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.